|
Tuesday, 08/03/2010
|
Estimating the Subject by Treatment Interaction in Nonreplicated Crossover Diet Studies
Matthew Kramer, Agricultural Research Service; Shirley C. Chen, Agricultural Research Service; Sarah Gebauer, Agricultural Research Service; David Baer, Agricultural Research Service
|
Sample Size Re-estimation in Crossover Trials
Adina Soaita, Pfizer Inc.; Byron Jones, Pfizer Inc.; Jerry J. Weaver, Pfizer Inc.
10:35 AM
|
Comparing Adaptive and Traditional Crossover Designs for Dose-Finding Trials
James A. Bolognese, Cytel Inc.; Nitin R. Patel, Cytel Inc.; Byron Jones, Pfizer Inc.
11:15 AM
|
Optimal Crossover Designs for PK Studies
Sergei Leonov, GlaxoSmithKline; Valerii Fedorov, GlaxoSmithKline; Byron Jones, Pfizer Inc.
11:55 AM
|
Estimation Bias in Complete-Case Analysis in Crossover Studies with Missing Data
Fang Liu, Merck Research Laboratories
2:05 PM
|
Analysis of a 2-by-2 Crossover Trial of Binary Data with Missing Values Using Multiple Imputation
Junxiang Luo, Eli Lilly and Company; Timothy Costigan, Eli Lilly and Company; Eileen Brown, Eli Lilly and Company
2:20 PM
|
|
Thursday, 08/05/2010
|
An Improved Analytic Method for 2x2 Crossover Trials with Potential Missing Data
Yu Ding, Merck Research Laboratories; Yang Liu, Merck Research Laboratories; Devan V. Mehrotra, Merck Research Laboratories; John Palcza , Merck Research Laboratories
8:35 AM
|
Adjusting for Baseline Measurements in Crossover Studies
Chengcheng Liu, Merck & Co., Inc.; Lingling Han, Merck & Co., Inc.; Xiaodong Li, Merck & Co., Inc.; Peng Sun, Merck & Co., Inc.
8:50 AM
|
Impact of Missing Data on the Analysis of Crossover Data
Anjela Tzontcheva, Merck & Co., Inc.; Mahtab Marker, Merck & Co., Inc.
9:05 AM
|
Selecting Covariance Structures in 3, 4, and 6 Period PK and PD Crossover Trials
Deborah Panebianco, Merck & Co., Inc.; Tom Bradstreet, Merck & Co., Inc.; Andrea Maes, Novartis Pharmaceuticals Corporation; Lata Maganti, Merck & Co., Inc.
9:20 AM
|
How to Handle Placebo Data in Dosing Ranging Studies Using 2-by-2 Crossover Design
Xin Zhao, Merck & Co., Inc.
9:35 AM
|
|